News & Updates

Treatment with the novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist ecnoglutide for weight management is safe and results in substantial and sustained weight loss in adults with obesity or overweight but without diabetes, according to a phase III study.

In adolescents with homozygous familial hypercholesterolemia (HoFH), treatment with inclisiran appears to be safe and efficacious for reducing low-density lipoprotein cholesterol (LDL-C) levels, according to the results of the first part of the phase III ORION-13* trial.

Treatment with semaglutide may offer some advantage over empagliflozin, with a recent study showing a much lower risk of death and cardiovascular (CV) events among patients with type 2 diabetes (T2D) who received semaglutide.

Polytrauma patients with obesity appear to have a lower risk of death and shorter length of hospital stays, suggests a study.

Former Dean of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK), Choh-Ming Li Professor of Medicine and Therapeutics, codirector of Microbiota I-Center (MagIC), Gastroenterologist

Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.

Children with hidradenitis suppurativa (HS) are prone to a number of metabolic, endocrinologic, dermatologic, psychiatric, and genetic comorbidities, including obesity, anxiety, and acne vulgaris, according to the findings of a systematic review and meta-analysis.